Sarepta Therapeutics, Inc. SRPT
18.54 USD +0.22 (+1.20%)
At closeNov 3, 2026, 4:00 PM EST
18.54 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
18.29 Day range 18.81
14.68 52-week range 24.68
- YTD
- -13.85%
- 1 year
- -24.17%
Analyst view
Consensus: hold
Hold
Price target (mean) 21.64 +16.7% upside
Now 18.54
- Target (low)
- 5.00
- Target (mean)
- 21.64
- Target (high)
- 38.00
Ratings (0m) 24 7 buy · 12 hold · 5 sell
- Strong buy0
- Buy7
- Hold12
- Sell3
- Strong sell2
Recommendation trend
- This month 24
- 1 month ago 24
- 2 months ago 24
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.35734 | -0.06043 – 1.06 | -0.13 | +374.9% | 350.10M | -12.3% | 10 |
| Next quarter | 0.11677 | -1.07 – 1.05 | -3.58 | +103.3% | 349.56M | -21.1% | 10 |
| Current year | 4.32 | 2.88 – 5.90 | -5.05 | +185.6% | 1.83B | -16.7% | 10 |
| Next year | 2.45 | 0.53327 – 4.79 | 4.32 | -43.3% | 1.38B | -24.6% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Oct 5, 2026 | HC Wainwright & Co. | Reiterated | Sell | Sell |
| Sep 30, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Sep 28, 2026 | Needham | Reiterated | Underperform | Underperform |
| Jul 9, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Jul 9, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Apr 16, 2026 | HC Wainwright & Co. | Reiterated | Sell | Sell |
| Mar 26, 2026 | Citigroup | Maintained | Sell | Sell |
| Mar 26, 2026 | Needham | Reiterated | Underperform | Underperform |
| Mar 19, 2026 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 13, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Citigroup | Maintained | Sell | Sell |
| Mar 2, 2026 | HC Wainwright & Co. | Reiterated | Sell | Sell |
| Feb 27, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jan 27, 2026 | HC Wainwright & Co. | Reiterated | Sell | Sell |
| Jan 23, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 14, 2026 | HC Wainwright & Co. | Reiterated | Sell | Sell |
| Dec 9, 2025 | Wedbush | Initiated | — | Outperform |
| Nov 5, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Nov 5, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 5, 2025 | Guggenheim | Maintained | Buy | Buy |
| Nov 5, 2025 | Mizuho | Upgrade | Neutral | Outperform |
| Nov 4, 2025 | Baird | Maintained | Neutral | Neutral |
| Oct 30, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Sep 22, 2025 | BMO Capital | Upgrade | Market Perform | Outperform |
| Sep 15, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Sep 9, 2025 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Aug 25, 2025 | HC Wainwright & Co. | Reiterated | Sell | Sell |
| Aug 21, 2025 | B of A Securities | Maintained | Underperform | Underperform |
| Aug 20, 2025 | B of A Securities | Maintained | Underperform | Underperform |